Suzette Kox named IGBA's new secretary general

21 February 2019

A woman who has been involved in biosimilars since work on their development first began two decades ago, has been named director general of the International Generic and Biosimilar medicines Association (IGBA).

For four years, Suzette Cox has been a senior director of the Biosimilar Medicines Group at Medicines for Europe, one of the members of IGBA, which was founded to strengthen cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world.

Her main role in her new position with the Switzerland-based group will be to coordinate the IGBA activities as the association continues to expand its outreach relevant to its mission, priorities and operations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK